Sonic Incytes has developed a breakthrough, point of care ultrasound solution for assessing and managing chronic liver disease—an emerging global health epidemic, affecting one in four persons worldwide.
Sonic Incytes' portable, handheld solution uses technology similar to MRI elastography, quantifying liver disease using 3D tissue sampling. It is a point of care solution that provides consistently accurate results, and a clear picture of liver health in real time, so that physicians can be confident in their diagnosis, treatment and care. In addition, the entire procedure takes about five minutes in a doctor’s office, contributing to a quick, safe and comfortable patient experience.
Our solution is redefining the standard of care in quantifying fatty liver disease—with diagnostic accuracy comparable to MRI—in the palm of your hand.
Sonic Incytes' portable, handheld solution uses technology similar to MRI elastography, quantifying liver disease using 3D tissue sampling. It is a point of care solution that provides consistently accurate results, and a clear picture of liver health in real time, so that physicians can be confident in their diagnosis, treatment and care. In addition, the entire procedure takes about five minutes in a doctor’s office, contributing to a quick, safe and comfortable patient experience.
Our solution is redefining the standard of care in quantifying fatty liver disease—with diagnostic accuracy comparable to MRI—in the palm of your hand.
Location: Canada, British Columbia, Vancouver
Employees: 11-50
Founded date: 2017
Investors 9
Mentions in press and media 3
| Date | Title | Description |
| 07.12.2021 | Sonic Incytes Medical Corp. Successfully Completes Series A Raise of US$7.3M to Accelerate Velacur™ Commercialization | VANCOUVER, British Columbia, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M Series A with backing from Nimbus Synergie... |
| 07.12.2021 | Sonic Incytes Medical Corp. Successfully Completes Series A Raise of US$7.3M to Accelerate Velacur™ Commercialization | VANCOUVER, British Columbia, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M Series A with backing from Nimbus Synergie... |
| 01.06.2020 | Sonic Incytes raises $3.5 million seed round to commercialize liver health assessment device | Sonic Incytes, a medical device startup based in Vancouver, has raised a $3.5 million CAD seed round. This startup’s funding raised to date now totals $4.5 million CAD. Investors in the round included non-profit research organization Genome... |